Terumo Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Terumo de 12.1% y 5.9% por año respectivamente. Se prevé que el BPA crezca en un 12.3% al año. Se espera que la rentabilidad financiera sea de 10.2% en 3 años.

Información clave

12.1%

Tasa de crecimiento de los beneficios

12.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	10.4%
Tasa de crecimiento de los ingresos	5.9%
Rentabilidad financiera futura	10.2%
Cobertura de analistas	Good
Última actualización	15 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

TSE:4543 - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	1,075,616	156,880	119,956	217,349	5
3/31/2026	1,038,752	142,623	103,466	199,418	12
3/31/2025	971,303	125,215	88,456	184,276	13
3/31/2024	905,114	108,274	60,893	143,841	13
12/31/2023	885,167	99,042	60,490	133,870	N/A
9/30/2023	860,767	99,096	35,316	110,769	N/A
6/30/2023	838,121	89,476	30,037	105,606	N/A
3/31/2023	820,209	89,325	45,363	117,536	N/A
12/31/2022	797,814	87,297	47,491	117,976	N/A
9/30/2022	761,982	79,146	65,356	135,078	N/A
6/30/2022	728,927	83,316	65,052	134,924	N/A
3/31/2022	703,303	88,813	67,362	141,467	N/A
12/31/2021	688,696	90,363	69,610	146,371	N/A
9/30/2021	675,183	95,414	69,307	146,611	N/A
6/30/2021	654,260	91,161	53,415	133,980	N/A
3/31/2021	613,842	77,268	38,573	121,485	N/A
12/31/2020	607,381	76,919	27,594	117,626	N/A
9/30/2020	604,915	71,342	20,121	109,392	N/A
6/30/2020	607,669	76,422	28,116	115,667	N/A
3/31/2020	628,897	85,211	33,995	117,479	N/A
12/31/2019	626,016	89,868	35,756	109,420	N/A
9/30/2019	621,762	90,727	34,047	104,160	N/A
6/30/2019	608,987	84,170	38,464	100,340	N/A
3/31/2019	599,481	79,470	39,207	93,571	N/A
12/31/2018	594,429	84,305	N/A	N/A	N/A
9/30/2018	588,162	92,782	61,609	106,706	N/A
6/30/2018	591,483	93,095	N/A	N/A	N/A
3/31/2018	587,775	91,295	73,240	114,562	N/A
12/31/2017	576,725	85,888	N/A	N/A	N/A
9/30/2017	553,664	66,769	N/A	87,995	N/A
6/30/2017	528,957	60,406	N/A	N/A	N/A
3/31/2017	514,164	54,225	N/A	80,862	N/A
12/31/2016	503,429	39,014	N/A	N/A	N/A
9/30/2016	510,969	44,087	N/A	85,463	N/A
6/30/2016	520,885	46,282	N/A	N/A	N/A
3/31/2016	525,026	50,676	N/A	80,303	N/A
12/31/2015	522,296	48,528	N/A	N/A	N/A
9/30/2015	515,364	43,603	N/A	80,102	N/A
6/30/2015	503,221	44,580	N/A	N/A	N/A
3/31/2015	489,506	38,470	N/A	73,110	N/A
12/31/2014	485,301	30,626	N/A	N/A	N/A
9/30/2014	474,640	36,517	N/A	86,298	N/A
6/30/2014	471,214	33,534	N/A	N/A	N/A
3/31/2014	467,360	34,096	N/A	96,260	N/A
12/31/2013	451,805	59,203	N/A	N/A	N/A
9/30/2013	436,490	51,948	N/A	65,450	N/A
6/30/2013	417,517	47,811	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (12.1% al año) de 4543 es superior a la tasa de ahorro (0.2%).

Beneficios vs. Mercado: Se prevé que los beneficios (12.1% al año) de 4543 crezcan más rápidamente que el mercado JP (9.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 4543 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (5.9% al año) de 4543 crezcan más rápidamente que los del mercado JP (4.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.9% al año) de 4543 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 4543 sea baja dentro de 3 años (10.2%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Terumo Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Price target increased by 7.3% to JP¥5,548

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Recent updates

Investors Still Waiting For A Pull Back In Terumo Corporation (TSE:4543)

Consensus EPS estimates increase by 11%

Price target increased by 7.4% to JP¥3,136

Terumo (TSE:4543) Has Announced A Dividend Of ¥22.00

New minor risk - Dividend sustainability

Upcoming dividend of JP¥22.00 per share

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Is Terumo (TSE:4543) Using Too Much Debt?

Price target increased by 7.3% to JP¥5,548

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 26, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Upcoming dividend of JP¥22.00 per share at 1.1% yield

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Full year 2023 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Upcoming dividend of JP¥21.00 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥18.00 per share

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Less than half of directors are independent

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Full year 2022 earnings: EPS misses analyst expectations

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Less than half of directors are independent

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Upcoming dividend of JP¥16.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥29.22 (vs JP¥23.63 in 2Q 2021)

Upcoming dividend of JP¥15.00 per share

First quarter 2022 earnings released: EPS JP¥36.90 (vs JP¥18.57 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020)

Full year 2021 earnings released: EPS JP¥102 (vs JP¥114 in FY 2020)

Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022

Upcoming dividend of JP¥14.00 per share

New 90-day low: JP¥3,951

Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc.

Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd

New 90-day high: JP¥4,560

Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021

Third quarter 2021 earnings released: EPS JP¥35.40 (vs JP¥28.22 in 3Q 2020)

Revenue and earnings beat expectations

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021

Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020

Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.

Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.

Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020

Previsiones de crecimiento de beneficios e ingresos